公开(公告)号：US11879893B2

公开(公告)日：2024-01-23

申请号：US17883833

申请日：2022-08-09

申请人： NLC Pharma Ltd

发明人： Dorit Arad

IPC分类号： G01N33/569 ,  B01L3/00

CPC分类号： G01N33/56983 ,  B01L3/5027 ,  G01N2469/10

摘要： The present invention is directed towards methods, compositions and kits for testing SARS-CO-V2 virus in a sample. The methods determine the presence of a viral 3CL protease by contacting the sample with a peptide compound capable of being cleaved by the protease to form peptide compound fragments. Detection of a peptide compound fragment confirms the presence of the virus.

公开(公告)号：US20240130983A1

公开(公告)日：2024-04-25

申请号：US18393798

申请日：2023-12-22

申请人： NLC Pharma Ltd

发明人： Dorit ARAD

IPC分类号： A61K31/122 ,  A61K9/00 ,  A61K9/127 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K31/198 ,  A61K31/222 ,  A61K31/381 ,  A61K31/40 ,  A61K31/422 ,  A61K31/433 ,  A61K31/454 ,  A61K31/513 ,  A61K31/536 ,  A61K36/30 ,  A61P31/14

CPC分类号： A61K31/122 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/127 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2095 ,  A61K9/282 ,  A61K9/2833 ,  A61K9/4833 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/198 ,  A61K31/222 ,  A61K31/381 ,  A61K31/40 ,  A61K31/422 ,  A61K31/433 ,  A61K31/454 ,  A61K31/513 ,  A61K31/536 ,  A61K36/30 ,  A61P31/14 ,  A61K2236/51

摘要： Described herein are compounds of Formula I:




wherein R1-R6 are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3CL protease, by contacting the 3CL protease with a compound of Formula I; as well as methods pharmaceutical composition comprising a compound of Formula I and at least one phospholipid, wherein a weight ratio of the phospholipid(s) to the compound in the composition is in a range of from 10:1 to 1:10. Further described herein is a method of treating a coronavirus infection in a subject in need thereof, by administering to the subject at least one compound that exhibits at least two of: inhibition of an activity of a 3CL protease of the coronavirus; inhibition of inflammation in the subject; and inhibition of autophagy in the subject.

公开(公告)号：US11857517B2

公开(公告)日：2024-01-02

申请号：US17887461

申请日：2022-08-14

申请人： NLC Pharma Ltd

发明人： Dorit Arad

IPC分类号： A61K31/122 ,  A61P31/14 ,  A61K9/00 ,  A61K9/127 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K31/198 ,  A61K31/222 ,  A61K31/381 ,  A61K31/40 ,  A61K31/422 ,  A61K31/433 ,  A61K31/454 ,  A61K31/513 ,  A61K31/536 ,  A61K36/30

CPC分类号： A61K31/122 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/127 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2095 ,  A61K9/282 ,  A61K9/2833 ,  A61K9/4833 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/198 ,  A61K31/222 ,  A61K31/381 ,  A61K31/40 ,  A61K31/422 ,  A61K31/433 ,  A61K31/454 ,  A61K31/513 ,  A61K31/536 ,  A61K36/30 ,  A61P31/14 ,  A61K2236/51

摘要： Described herein are compounds of Formula I:




wherein R1-R6 are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3CL protease, by contacting the 3CL protease with a compound of Formula I; as well as methods pharmaceutical composition comprising a compound of Formula I and at least one phospholipid, wherein a weight ratio of the phospholipid(s) to the compound in the composition is in a range of from 10:1 to 1:10. Further described herein is a method of treating a coronavirus infection in a subject in need thereof, by administering to the subject at least one compound that exhibits at least two of: inhibition of an activity of a 3CL protease of the coronavirus; inhibition of inflammation in the subject; and inhibition of autophagy in the subject.

公开(公告)号：US20220387354A1

公开(公告)日：2022-12-08

申请号：US17887461

申请日：2022-08-14

申请人： NLC Pharma Ltd

发明人： Dorit ARAD

IPC分类号： A61K31/122 ,  A61P31/14 ,  A61K9/48 ,  A61K36/30 ,  A61K9/00 ,  A61K9/20 ,  A61K9/28 ,  A61K9/127 ,  A61K31/198 ,  A61K31/381 ,  A61K31/454 ,  A61K31/422 ,  A61K31/433 ,  A61K31/40 ,  A61K31/536 ,  A61K31/222 ,  A61K31/513

摘要： Described herein are compounds of Formula I: wherein R1-R6 are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3CL protease, by contacting the 3CL protease with a compound of Formula I; as well as methods pharmaceutical composition comprising a compound of Formula I and at least one phospholipid, wherein a weight ratio of the phospholipid(s) to the compound in the composition is in a range of from 10:1 to 1:10. Further described herein is a method of treating a coronavirus infection in a subject in need thereof, by administering to the subject at least one compound that exhibits at least two of: inhibition of an activity of a 3CL protease of the coronavirus; inhibition of inflammation in the subject; and inhibition of autophagy in the subject.

公开(公告)号：US20230090502A1

公开(公告)日：2023-03-23

申请号：US17883833

申请日：2022-08-09

申请人： NLC Pharma Ltd

发明人： Dorit ARAD

IPC分类号： G01N33/569 ,  B01L3/00

摘要： The present invention is directed towards methods, compositions and kits for testing SARS-CO-V2 virus in a sample. The methods determine the presence of a viral 3CL protease by contacting the sample with a peptide compound capable of being cleaved by the protease to form peptide compound fragments. Detection of a peptide compound fragment confirms the presence of the virus.